Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.
Viridian Therapeutics, Inc. develops antibody-based medicines for autoimmune and rare diseases, with a central focus on thyroid eye disease. Its TED portfolio includes veligrotug, an intravenously administered humanized monoclonal antibody targeting IGF-1R, and elegrobart, a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R.
Recurring company news covers clinical results from the THRIVE and REVEAL programs, regulatory updates for biologics applications, commercial preparation for TED therapies, and progress across earlier pipeline work, including anti-TSHR and FcRn inhibitor programs. Viridian also reports financial results, public equity and convertible-note financings, royalty-related funding updates, and Nasdaq inducement equity grants tied to employee compensation.
Viridian Therapeutics (NASDAQ: VRDN) announced a webcast and conference call on March 8, 2023, at 8:00 a.m. ET to discuss its Q4 and full-year 2022 financial results. The session can be accessed via the company’s website under the ‘Events and Presentations’ section. Viridian focuses on developing best-in-class medicines for serious and rare diseases, with ongoing clinical trials for its lead candidate, VRDN-001, targeting thyroid eye disease (TED). The company is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 trial, broadening its pipeline with additional candidates aimed at improving treatment delivery for TED patients.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its senior management will present at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation will be available in the Investors section of Viridian's website. The company specializes in developing innovative medicines for serious and rare diseases, focusing on thyroid eye disease (TED). Currently, Viridian is advancing VRDN-001 through a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial. The company aims to offer convenient treatment options for TED patients.
Viridian Therapeutics, a biopharmaceutical company focused on serious and rare diseases, will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. The event will be accessible via a live webcast on Viridian's website, and a replay will be available afterward. Viridian is advancing its VRDN-001 candidate in global Phase 3 and Phase 2 trials for thyroid eye disease, aiming to deliver best-in-class therapies. The company also develops other candidates targeting autoimmune and rare diseases. For more information, visit viridiantherapeutics.com.
Viridian Therapeutics Appoints New CEO
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company, announced the appointment of Scott Myers as President and CEO, effective February 6, 2023. Myers has over 30 years of experience in the biopharmaceutical sector, succeeding co-founder Jonathan Violin, Ph.D. Under Violin's leadership, the company advanced its first Phase 3 trial in Thyroid Eye Disease (TED). Myers aims to leverage his extensive background to transition Viridian into a fully-integrated biopharmaceutical company, focusing on clinical execution and growth. Additionally, he received an inducement award comprising stock options and restricted stock units.
Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced on February 2, 2023, that its Compensation Committee approved the grant of non-qualified stock options to purchase 332,000 shares to four new employees. This Inducement Grant, made outside the Amended and Restated 2016 Equity Incentive Plan, was essential for the new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price matches the common stock's closing price on the Grant Date, with shares vesting over four years. The company is focused on creating innovative treatments for serious and rare diseases, particularly advancing candidates for thyroid eye disease.
Viridian Therapeutics (VRDN) announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for active thyroid eye disease (TED). In the latest cohort, 3 mg/kg showed significant improvements: 67% of patients were proptosis responders, and 56% overall responders. Across all cohorts, 71% were proptosis responders, with a favorable safety profile noted. The data support a planned once-monthly subcutaneous dosing for VRDN-002 and VRDN-003. The company is progressing towards pivotal trials and expects to advance its subcutaneous program as a convenient treatment option.
Viridian Therapeutics (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PST in San Francisco. Alongside the presentation, a live Q&A session will begin at 2:35 p.m. PST. Investors can access the live webcast on the company's website, with a replay available until February 8, 2023. Viridian is focused on developing treatments for serious diseases, including ongoing clinical trials for VRDN-001 targeting thyroid eye disease.
Viridian Therapeutics (NASDAQ: VRDN) has enrolled its first patient in the global THRIVE Phase 3 trial, evaluating the investigational agent VRDN-001 for active thyroid eye disease (TED). The trial involves around 120 patients across 50 centers in North America and Europe, aiming for topline results by mid-2024. VRDN-001, a monoclonal antibody targeting IGF-1R, has shown promising efficacy in preliminary studies. The company also plans a second Phase 3 trial for chronic TED, further supporting its commitment to improving treatment options for patients.
Viridian Therapeutics (Nasdaq: VRDN) announced the grant of non-qualified stock options to an employee for 215,000 shares of common stock, approved by its Compensation Committee. This Inducement Grant, dated December 1, 2022, is outside the 2016 Equity Incentive Plan but adheres to its terms. The exercise price aligns with the stock's closing price on the grant date, and shares will vest over four years. Viridian focuses on treatments for serious diseases, with its lead program targeting thyroid eye disease (TED) through differentiated monoclonal antibodies.
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022. The conference will feature a fireside chat at 10:30 a.m. ET, available via a live webcast on the company's website. Viridian is focused on developing innovative treatments for serious diseases, notably through its monoclonal antibody programs targeting thyroid eye disease (TED). Key products include VRDN-001, VRDN-002, and VRDN-003, which offer convenient dosing options for patients suffering from TED.